Anzeige
Mehr »
Login
Dienstag, 22.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Der Megatrend 2025: Die unterschätzte Chance im Uranmarkt - was diese Aktie JETZT interessant macht!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A110TG | ISIN: IL0011316309 | Ticker-Symbol: M8W
Frankfurt
22.04.25
08:16 Uhr
15,100 Euro
+1,000
+7,09 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
MEDIWOUND LTD Chart 1 Jahr
5-Tage-Chart
MEDIWOUND LTD 5-Tage-Chart
RealtimeGeldBriefZeit
15,10015,60013:19

Aktuelle News zur MEDIWOUND Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
07.04.MediWound Ltd. - 6-K, Report of foreign issuer2
19.03.MediWound files to sell $125M mixed securities shelf, 1.26M ordinary shares for holders2
MEDIWOUND Aktie jetzt für 0€ handeln
19.03.MediWound Ltd. Q4 Loss Increases, But Beats Estimates2
19.03.MediWound Ltd. - S-8, Securities to be offered to employees in employee benefit plans-
19.03.MediWound Ltd. - 20-F, Annual and transition report of foreign private issuers3
19.03.MediWound GAAP EPS of -$0.36 beats by $0.23, revenue of $5.84M beats by $0.09M1
19.03.MediWound Ltd.: MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update447Initiated VALUE, a global Phase III pivotal trial of EscharEx® for venous leg ulcers Expanded strategic research collaborations with industry leaders, now including Kerecis $20 million in revenue...
► Artikel lesen
19.03.MediWound Ltd. - 6-K, Report of foreign issuer-
18.03.MediWound Q4 2024 Earnings Preview1
28.02.Craig-Hallum sets $39 target on MediWound stock with buy rating1
12.02.MediWound stock climbs 4% on Phase 3 study initiation1
12.02.MediWound Ltd.: MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx for Treatment of Venous Leg Ulcers172Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure Interim analysis planned after 65% of patients complete treatment, expected...
► Artikel lesen
12.02.MediWound Ltd. - 6-K, Report of foreign issuer-
08.01.MediWound Ltd. - 6-K, Report of foreign issuer5
16.12.24MediWound Ltd. - 6-K, Report of foreign issuer1
26.11.24MediWound Ltd. Q3 Loss Increases, Misses Estimates1
26.11.24MediWound GAAP EPS of -$0.98 misses by $0.53, revenue of $4.35M misses by $1.66M3
26.11.24MediWound Ltd.: MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update336EscharEx IND Submission by Year-End; Phase 3 Study to Begin Shortly Thereafter; KOL Event Set for January 8, 2025 FDA Approves NexoBrid for Pediatric Use $25 Million Financing and €16.25 Million...
► Artikel lesen
26.11.24MediWound Ltd. - 6-K, Report of foreign issuer-
25.11.24MediWound Q3 2024 Earnings Preview1
Seite:  Weiter >>
27 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1